Immunotherapy (Cancer)
Principles of cancer immunotherapy and toxicity management.
Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
Clinical Guidelines
ESMO Clinical Practice Guidelines: Management of toxicities from immunotherapy
National
ESMO Clinical Practice Guidelines: Management of toxicities from immunotherapyNational
ASCO Guideline: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor TherapyLocal
ESMO Clinical Practice Guideline: Management of toxicities from immunotherapyLocal
ESMO Clinical Practice Guideline: Management of toxicities from immunotherapyLocal
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaLocal
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaLocal
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinomaLocal
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinomaLocal
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinomaLocal
Society for Immunotherapy of Cancer (SITC) consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Local
Society for Immunotherapy of Cancer (SITC) consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Local
Society for Immunotherapy of Cancer (SITC) consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Local
Society for Immunotherapy of Cancer (SITC) consensus statement on immunotherapy for the treatment of prostate cancerLocal
Society for Immunotherapy of Cancer (SITC) consensus statement on immunotherapy for the treatment of urologic cancersLocal